Short Interest in ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) Expands By 21.3%

ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) was the target of a large growth in short interest during the month of August. As of August 31st, there was short interest totalling 49,600 shares, a growth of 21.3% from the August 15th total of 40,900 shares. Currently, 4.7% of the shares of the stock are short sold. Based on an average daily volume of 134,500 shares, the short-interest ratio is currently 0.4 days.

ZyVersa Therapeutics Price Performance

ZVSA opened at $2.38 on Tuesday. The firm has a 50-day simple moving average of $3.34 and a two-hundred day simple moving average of $5.01. ZyVersa Therapeutics has a 52 week low of $2.08 and a 52 week high of $62.30.

ZyVersa Therapeutics (NASDAQ:ZVSA) last announced its quarterly earnings results on Friday, August 9th. The company reported ($3.31) EPS for the quarter, beating analysts’ consensus estimates of ($5.20) by $1.89. As a group, equities research analysts anticipate that ZyVersa Therapeutics will post -22.7 EPS for the current fiscal year.

About ZyVersa Therapeutics

ZyVersa Therapeutics, Inc, a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. The company develops drug development platforms, including Cholesterol Efflux Mediator VAR 200, an injectable drug, which is in Phase 2a clinical trial to the treatment of renal indications, such as focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney diseases; and Inflammasome ASC Inhibitor IC 100, a humanized monoclonal antibody that is in preclinical stage for treatment of inflammatory diseases comprising acute respiratory syndrome, multiple sclerosis, IgA neuropathy, pancreatic cancer, Parkinson's and Huntington's disease, atherosclerosis, Alzheimer's disease, and obesity.